FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Г										
	OMB APPROVAL									
ı										
l	OMB Number:	3235-0287								
l	Estimated average burden									
l	hours per response	: 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

						Т .						прапу Аст с), IO+C	,							
1. Name a	2. Issuer Name and Ticker or Trading Symbol Frequency Therapeutics, Inc. [FREQ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)												
Lucchino David L.															X	Direc	tor		10% Ov	vner	
(Last)	st) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year)								X	Office belov	er (give title v)		Other (s below)	specify	
C/O FREQUENCY THERAPEUTICS, INC.						00/02	08/02/2023										President and CEO				
						4 16 0	A If Amondment Date of Original Ellad (Atauth/David)									6 Individual or Jaint/Croup Filing (Charle Applicable					
75 HAYDEN AVE, SUITE 300							4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)																Form filed by One Reporting Person				on	
LEXING	EXINGTON MA 02421														Form filed by More than One Reporting Person						
(City)	Rule 10b5-1(c) Transaction Indication																				
							Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
			Table I	- No	n-Deriva	tive S	ecur	ities	Acc	uired,	Dis	posed of	f, or I	3ene	ficiall	ly Owr	ned				
1. Title of Security (Instr. 3) 2. Transaction						Execution Date,			3. 4. Securities Acquired (A Disposed Of (D) (Instr. 3,								6. Ownership Form: Direct		7. Nature of Indirect		
(Month/Day/					Code (Instr. 5)				(-) (o o, 4 c			Beneficially Owned Following		(D) or Indirect (I) (Instr. 4)		Beneficial Ownership (Instr. 4)					
										Code	v	Amount	(A) (D)	or Pr	ice		ted action(s) 3 and 4)	ľ			
Common Stock 08/02/20							023			S		2,587(1)	Г	\$).52 ⁽²⁾	670,021			D		
Common Stock 08/03/20						023				S		2,679(1)	Г	\$().59 ⁽³⁾	667,342		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
					(e.g., pu	ts, cal	ls, v	varra	ants,	option	ıs, c	convertib	le se	curit	ies)						
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, ity or Exercise (Month/Day/Year) if any			ition Date,	4. Transaction Code (Instr. 8)		Secu Acqu (A) o Disp of (D	vative irities uired or osed) r. 3, 4	6. Date Expirati (Month/	on Da		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and		De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)		
						Code V		(A)	(D)	Date Exercisable		Expiration Date	Title	Amou or Numb of Share	er						

Explanation of Responses:

- 1. Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person.
- 2. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$0.480 to \$0.543. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- 3. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$0.555 to \$0.598. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

/s/ James P. Abely, Attorney-08/04/2023 in-Fact for David L. Lucchino

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.